Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who had had a recent acute coronary syndrome. METHODS: We randomly assigned patients with type 2 diabetes and either an acute myocardial infarction or unstable angina requiring hospitalization within the previous 15 to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic and cardiovascular drug therapy. The study design was a double-blind, noninferiority trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the primary end point of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 5380 patients underwent randomization and were followed for up to 40 months (median, 18 months). A primary end-point event occurred in 305 patients assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (hazard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower with alogliptin than with placebo (mean difference, -0.36 percentage points; P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis were similar with alogliptin and placebo. CONCLUSIONS: Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Development Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DPP-4 inhibitors do not have significant GI adverse effects and may be used in early combination with metformin.1038–1043”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1038]
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [20]
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
In the citing paper
“GLP-1 agents, including dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagon-like peptide-1 receptor agonist (GLP-1 Ra), enhance insulin secretion in pancreatic b-cell and showed many benefits in treating diabetes mellitus type 2 but are not a common choice for GDM [117,118].”
From Gestational Diabetes Mellitus—Recent Literature Review (2022) · cites this paper as [117]
In the citing paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
From Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015) · cites this paper as [5]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Self-citationUniversal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Task Force Members, Thygesen, K., Alpert, J. S., White, H. D., Biomarker Group, Jaffe, A. S., Apple, F. S., Galvani, M., Katus, H. A., Newby, L. K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm355 · Cited by 2,541
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Cited by
Items 501–600 of 1,012
Therapeutic strategies utilizing SDF-1α in ischaemic cardiomyopathy
Ziff, O. J., Bromage, D. I., Yellon, D. M., & Davidson, S. M. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx203 · Cited by 60
“EXAMINE compared Alogliptin with placebo in 5380 patients with type 2 diabetes mellitus (T2DM) and recent acute coronary syndrome over median follow-up of 18 months and found no significant difference in the primary composite endpoint (CV death, non-fatal MI or non-fatal stroke) or in all-cause mortality or HF hospita…”
MethodTratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2017.12.003 · Cited by 70
Bretón‐Romero, R., Weisbrod, R. M., Feng, B., Holbrook, M., Ko, D., Stathos, M. M., Zhang, J., Fetterman, J. L., & Hamburg, N. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009379 · Cited by 54
Documento de abordaje integral de la diabetes tipo 2
Reyes‐García, R., Moreno, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Escalada, J., et al. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.10.010 · Cited by 59
Avogaro, A., Bonora, E., Consoli, A., Prato, S. D., Genovese, S., & Giorgino, F. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119845612 · Cited by 63
Updates on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0610-y · Cited by 52
“SAVIOR-TIMI53 and EXAMINE however indicated an increase in risk of hospitalization for HF [12, 13].”
BackgroundHeart failure and type 2 diabetes: From cardiovascular outcome trials, with hope
Giugliano, D., Meier, J. J., & Esposito, K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13629 · Cited by 52
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13960 · Cited by 60
Mogensen, U. M., Andersson, C., Fosbøl, E. L., Schramm, T. K., Vaag, A. A., Scheller, N. M., Torp-Pedersen, C. T., Gislason, G., & Køber, L. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12314 · Cited by 59
“Our findings of no increased risk of CV events associated with DPP-4 inhibitors are consistent with two previous studies in a ‘real world setting’ [22,23] and two recent large clinical trials [13,14].”
BackgroundMethodResultInfluentialChan, C.-W., Yu, C.-L., Lin, J.-C., Hsieh, Y.-C., Lin, C.-C., Hung, C.-Y., Li, C.-H., Liao, Y.-C., Lo, C.-P., Huang, J.-L., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0663-6 · Cited by 51
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Do Current Clinical Trials Meet Society’s Needs?
Pocock, S., & Gersh, B. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.08.008 · Cited by 54
“The SAVOR–TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis In Myocardial Infarction 53) trial of saxagliptin (25) and the EXAMINE (Examination of Cardiovascular Outcomes with Algorithms versus Standard of Care) trial of alogliptin (26) showed no effects on t…”
MethodIncretin-Based Drugs and the Risk of Congestive Heart Failure
Yu, O. H. Y., Filion, K. B., Azoulay, L., Patenaude, V., Majdan, A., & Suissa, S. (2015) · Diabetes Care · doi:10.2337/dc14-1459 · Cited by 53
“as the reference category to facilitate comparison with SAVOR-TIMI 53 (2) and EXAMINE (20); in these trials, the active drugs or placebo was added to a heterogeneous background of antidiabetic agents.”
InfluentialWhere Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
Ahmad, E., Sargeant, J. A., Zaccardi, F., Khunti, K., Webb, D. R., & Davies, M. J. (2020) · Pharmaceuticals · doi:10.3390/ph13120427 · Cited by 59
Faber, R., Zander, M., Pena, A., Michelsen, M. M., Mygind, N. D., & Prescott, E. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0206-3 · Cited by 51
“(enzyme responsible for the degradation of GLP-1) on the cardiovascular system came out neutral [31,32].”
BackgroundMcGovern, A. P., Hinton, W., Correa, A., Munro, N. M., Whyte, M., & de Lusignan, S. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012801 · Cited by 55
Nyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.12.004 · Cited by 52
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
2020 vision – An overview of prospects for diabetes management and prevention in the next decade
Wang, C., Neil, D. L., & Home, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.007 · Cited by 57
Sharma, A., Mentz, R. J., Granger, B. B., Heitner, J. F., Cooper, L. B., Banerjee, D., Green, C. L., Majumdar, M. D., Eapen, Z., Hudson, L., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.01.007 · Cited by 52
Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 50
“Endotheliumdependent vasodilation in response to acetylcholine was improved in preconstricted aortic rings isolated from WDfed Apoe / mice treated with liraglutide versus the control, which was abolished by cotreatment with the GLP1R antagonist exendin(9-39) (19).”
BackgroundYandrapalli, S., Jolly, G., Horblitt, A., Sanaani, A., & Aronow, W. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1358064 · Cited by 50
“gliptin or placebo in addition to existing antihyperglycemic and CV drug therapy for a median follow up of 40 months [93].”
MethodCardiovascular Implications of Hypoglycemia in Diabetes Mellitus
Connelly, K. A., Yan, A. T.-K., Leiter, L. A., Bhatt, D. L., & Verma, S. (2015) · Circulation · doi:10.1161/circulationaha.115.015946 · Cited by 54
Liu, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.9090 · Cited by 49
Mechanisms linking empagliflozin to cardiovascular and renal protection
Filardi, P. P., Avogaro, A., Bonora, E., Colivicchi, F., Fioretto, P., Maggioni, A. P., Sesti, G., & Ferrannini, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.089 · Cited by 56
Liraglutide and Glycaemic Outcomes in the LEADER Trial
Zinman, B., Nauck, M. A., Bosch‐Traberg, H., Frimer‐Larsen, H., Ørsted, D. D., & Buse, J. B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0524-z · Cited by 60
The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus
Hussain, S. T., & Chowdhury, T. A. (2019) · Drugs · doi:10.1007/s40265-019-1061-4 · Cited by 58
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.12.005 · Cited by 51
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“It is worthy to note that there were no cases of pancreatic cancer reported in this trial [118].”
BackgroundMethodResultInfluentialBertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
“Gliptins have also recently been shown to have no effect on major cardiovascular events in T2D (Udell et al., 2015; White et al., 2013).”
BackgroundAge and Sex Differences in Efficacy of Treatments for Type 2 Diabetes: A Network Meta-Analysis
Hanlon, P., Butterly, E. W., Wei, L. S., Wightman, H., Almazam, S. A., Alsallumi, K., Crowther, J., McChrystal, R., Rennison, H., Hughes, K., et al. (2025) · JAMA · doi:10.1001/jama.2024.27402 · Cited by 64
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 68
Takebayashi, K., & Inukai, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3112w · Cited by 52
“In contrast, a beneficial effect on cardiovascular events could not be proved using dipeptidyl peptidase 4 (DPP4) inhibitors [4-6], another widely used class of antidiabetic agents.”
BackgroundAntidiabetic drugs and stroke risk. Current evidence
Castilla‐Guerra, L., Fernández‐Moreno, M. D. C., Jiménez, D. L., & Nimo, E. C. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.09.019 · Cited by 49
“On thebasis of thisfinding, the FDA issued a warning regarding the risk of heart failure for saxagliptin [29] The warning also included alogliptin, for which heart Please cite this article as: Castilla-Guerra L, et al, Antidiabetic drugs and str 10.1016/j.ejim.2017.09.019 failure risk is unclear because it was not ass…”
BackgroundInfluentialJensen, T. M., Saha, K., & Steinberg, W. M. (2015) · Diabetes Care · doi:10.2337/dc13-1210 · Cited by 48
“50) compared with placebo, with a numerical imbalance between arms (47,48).”
BackgroundChen, D., Wang, S.-H., Mao, C., Tsai, M., Lin, Y., Chou, C., Wen, M., Wang, C., Hsieh, C., Hung, K., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.12.029 · Cited by 49
“The recently completed EXAMINE trial suggested the DPP-4 inhibitor, alogliptin, did not increase the rate of major adverse cardiovascular events in patients with T2DM who had recent acute coronary syndrome (25).”
BackgroundPharmacologic Management of Type 2 Diabetes: 2016 Interim Update
(2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.02.006 · Cited by 53
DPP4 as a Potential Candidate in Cardiovascular Disease
Chen, S.-Y., Kong, X.-Q., Zhang, K.-F., Luo, S., Wang, F., & Zhang, J. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s380285 · Cited by 56
“The risk of MACE was similar in patients in the DPP4 inhibitor and placebo group, demonstrating the cardiovascular safety of alogliptin and saxagliptin.(5,6) Similarly, the”
ResultYao, M., Hao, Y., Wang, T., Xie, M., Li, H., Feng, J., Feng, L., & Ma, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1149671 · Cited by 55
Treatment of type 2 diabetes patients with heart conditions
Aktaş, G., Tel, B. M. A., Tel, M. R., & Balci, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204941 · Cited by 51
“Patients on alogliptin treatment were analyzed, and higher HF risk was found in this population compared to the control subjects receiving placebo [19].”
BackgroundFirst novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus
Kaku, K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1099630 · Cited by 50
Antidiabetic Agents and Endothelial Dysfunction – Beyond Glucose Control
Eriksson, L., & Nyström, T. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12402 · Cited by 52
Davis, T. M. E. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12295 · Cited by 50
“Although the original rationale for cardiovascular safety studies of new blood glucose-lowering therapies now appears questionable [72], SAVOR TIMI 53 and EXAMINE have provided useful data beyond rates of cardiovascular events whereas TECOS and CAROLINA will add substantially to the DPP-4 inhibitor safety database.”
BackgroundMethodResultInfluentialDipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
Terawaki, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Takahashi, H., Tanaka, T., Murase, K., Nagaishi, R., Tanabe, M., & Yanase, T. (2014) · Cardiovascular Diabetology · doi:10.1186/preaccept-9752811371415510 · Cited by 51
DPP-4 inhibition has beneficial effects on the heart after myocardial infarction
Kubota, A., Takano, H., Wang, H., Hasegawa, H., Tadokoro, H., Hirose, M., Kobara, Y., Yamada-Inagawa, T., Komuro, I., & Kobayashi, Y. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.026 · Cited by 48
Mannucci, E., Mosenzon, O., & Avogaro, A. (2016) · Diabetes Care · doi:10.2337/dcs15-3024 · Cited by 48
“The available CV safety trials confirm the safety of DPP-4 inhibitors in this respect; in fact, no case of thyroid medullary carcinoma was reported in SAVOR-TIMI 53, EXAMINE, or TECOS (3–5).”
BackgroundMethodInfluentialMannucci, E., & Monami, M. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0432-4 · Cited by 49
“Randomized Controlled Trial Data We identified one primary article and one secondary article for the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial [28, 45], one primary article and two secondary articles for the Saxagliptin Assessment of Vascular Outcomes Recorded in Pa…”
BackgroundMethodResultInfluentialSchott, G., Martinez, Y. V., de Silva, R. E. E., Guiteras, A. R., Vögele, A., Reeves, D., Kunnamo, I., Marttila-Vaara, M., & Sönnichsen, A. C. (2017) · BMC Geriatrics · doi:10.1186/s12877-017-0571-8 · Cited by 51
“2013 [44] Multicentre, randomised, double-blind placebocontrolled trial LR UR LR UR LR LR HR LR Low risk of bias, HR High risk of bias, UR Unclear risk of bias The Author(s) BMC Geriatrics 2017, 17(Suppl 1):226 Page 32 of 157”
BackgroundMethodResultInfluentialRørth, R., Jhund, P. S., Mogensen, U. M., Kristensen, S. L., Petrie, M. C., Køber, L., & McMurray, J. J. V. (2018) · Diabetes Care · doi:10.2337/dc17-2583 · Cited by 53
Bonora, B. M., Cappellari, R., Albiero, M., Avogaro, A., & Fadini, G. P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00824 · Cited by 53
Lee, H., Chen, S., Liu, J., Li, P., Wu, L., Chang, S., Yeh, Y., Kuo, C.-T., Chan, Y., & See, L. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01118-0 · Cited by 58
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 54
“However, these compounds failed to show similar benefits in human trials [164].”
BackgroundThein, D., Christiansen, M. N., Mogensen, U. M., Bundgaard, J. S., Rørth, R., Madelaire, C., Fosbøl, E. L., Schou, M., Torp-Pedersen, C. T., Gislason, G., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01078-5 · Cited by 51
Mima, A., Nomura, A., & Fujii, T. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115032 · Cited by 49
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 60
Scheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0157-y · Cited by 49
“EXAMINE [53] Alogliptin 25 mg (n = 2,679) Placebo (n = 2,701) ALT [3 9 ULN 46 (1.”
BackgroundResultInfluentialEsposito, K., Chiodini, P., Capuano, A., Maiorino, M. I., Bellastella, G., & Giugliano, D. (2013) · Endocrine · doi:10.1007/s12020-013-0090-0 · Cited by 54
Li, J., Zheng, J., Wang, S., Lau, H. K., Fathi, A., & Wang, Q. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00015 · Cited by 47
“Nevertheless, clinical studies specifically designed to evaluate the potential cardiovascular benefits of 9-36a in patients with T2DM are warranted.”
BackgroundDei, A., Spigoni, V., Cito, M., Aldigeri, R., Ridolfi, V., Marchesi, E., Marina, M., Derlindati, E., Aloe, R., Bonadonna, R. C., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0503-0 · Cited by 48
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.357 · Cited by 54
“The CV safety of DPP4i has been demonstrated through the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53), the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE), and the Trial Evaluati…”
MethodTreatment of type 2 diabetes mellitus in elderly patients
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.12.004 · Cited by 54
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes
Wang, X., Zheng, P., Huang, G., Yang, L., & Zhou, Z. (2018) · Clinical and Experimental Medicine · doi:10.1007/s10238-018-0519-0 · Cited by 51
Phrommintikul, A., Wongcharoen, W., Kumfu, S., Jaiwongkam, T., Gunaparn, S., Chattipakorn, S. C., & Chattipakorn, N. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13903 · Cited by 54
The future of new drugs for diabetes management
Bailey, C. J., & Day, C. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107785 · Cited by 52
“Interpreting CVOTs The CVOTs are designed to assess CV safety by comparing major adverse CV events in groups of type 2 diabetes patients treated with particular glucose-lowering agents versus control (placebo), the latter group receiving ‘usual care’ with other classes of glucose-lowering therapies (Table 1) [16-32].”
BackgroundVasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
Wiciński, M., Górski, K. M., Wódkiewicz, E., Walczak, M., Nowaczewska, M., & Malinowski, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072275 · Cited by 53
Lee, S., Zhou, J., Leung, K. S. K., Wai, A. K. C., Jeevaratnam, K., King, E., Liu, T., Wong, W. T., Chang, C., Wong, I. C. K., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07319-x · Cited by 53
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 45
Stoian, A. P., Sachinidis, A. G., Stoica, R. A., Nikolić, D., Patti, A. M., & Rizvi, A. A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154295 · Cited by 48
Montilla, S., Marchesini, G., Sammarco, A., Trotta, M. P., Siviero, P. D., Tomino, C., Melchiorri, D., & Pani, L. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.07.014 · Cited by 49
“Later, the publication of two large cardiovascular outcome DPP-Is trials [13,22] and epidemiological data [23] stifled the debate; a 2014 joint Food and Drug Administration (FDA)eEuropean Medicines Agency (EMA) assessment concluded with a low-risk [24] but suggested continuous capture of data.”
BackgroundAoyama, M., Kawase, H., Bando, Y., Monji, A., & Murohara, T. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.002081 · Cited by 47
Ekström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Gudbjörnsdottir, S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 46
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
“To date, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) is the only study that showed superiority of incretinbased therapy against cardiovascular events compared to placebo. rial Patients ri ar site es lt ( is f R-TI I53 [57] (2.1 years) a a li ti 2.5 r / ( t i of esti…”
InfluentialThe effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Prat, L. I., & Tsochatzis, E. A. (2018) · HORMONES · doi:10.1007/s42000-018-0021-9 · Cited by 50
Sharma, A., Ambrosy, A. P., DeVore, A. D., Margulies, K. B., McNulty, S. E., Mentz, R. J., Hernandez, A. F., Michael Felker, G., Cooper, L. B., Lala, A., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12334 · Cited by 45
Mannucci, E., Nreu, B., Montereggi, C., Ragghianti, B., Gallo, M., Giaccari, A., Monami, M., Candido, R., Pintaudi, B., Targher, G., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.06.002 · Cited by 52
Avogaro, A., Dardano, A., de Kreutzenberg, S. V., & Prato, S. D. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12319 · Cited by 49
“More information can be drawn from two intervention trials, namely the Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (SAVOR-TIMI) and Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trials [81,82].”
MethodBethel, M. A., Green, J. B., Milton, J., Tajar, A., Engel, S. S., Califf, R. M., Holman, R. R., & on behalf of the TECOS Executive Committee (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12441 · Cited by 46
“Two other recently reported DPP-4 CV outcomes trials, the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial (EXAMINE, NCT00968708) [27] and the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction trial (SAVOR-T…”
ResultUse of incretin agents and risk of pancreatic cancer: a population‐based cohort study
Knapen, L. M., van Dalem, J., Keulemans, Y. C., van Erp, N. P., Bazelier, M. T., De Bruin, M. L., Leufkens, H. G. M., Croes, S., Neef, C., de Vries, F., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12605 · Cited by 43
“1 years) there were five cases of pancreatic cancer in the saxagliptin arm and 12 in the comparator agent arm, while no events of pancreatic cancer were reported in the alogliptin or placebo arm of the EXAMINE cardiovascular outcome trial (n= 5380, median follow-up 18 months) [12,13].”
BackgroundTanabe, M., Motonaga, R., Terawaki, Y., Nomiyama, T., & Yanase, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12567 · Cited by 47
Monami, M., Zannoni, S., Pala, L., Silverii, G. A., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.163 · Cited by 47
Pantalone, K. M., Misra‐Hebert, A. D., Hobbs, T. M., Wells, B. J., Kong, S. X., Chagin, K. M., Dey, T., Milinovich, A., Weng, W., Bauman, J. M., et al. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12613 · Cited by 51
“1 4186 (30) 6551 (30) 3239 (32) 2 2060 (15) 3083 (14) 1287 (13) ≥ 3 2289 (16) 3321 (15) 1089 (11)”
InfluentialComparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes
Kramer, C. K., Ye, C., Campbell, S., & Retnakaran, R. R. (2018) · JACC Heart Failure · doi:10.1016/j.jchf.2018.05.021 · Cited by 48
Cosentino, F., Ceriello, A., Baeres, F. M. M., Fioretto, P., Garber, A., Stough, W. G., George, J. T., Grant, P. J., Khunti, K., Langkilde, A. M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy677 · Cited by 44
Self-citationLim, S., Oh, T. J., Dawson, J., & Sattar, N. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13850 · Cited by 45
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 46
“SAVOR-TIMI 53 studied saxagliptin; EXAMINE, alogliptin; TECOS, sitagliptin; LEADER, liraglutide; SUSTAIN-6, semaglutide; EMPA-REG OUTCOME, empagliflozin; ELIXA, lixisenatide; and CANVAS, canagliflozin.”
BackgroundDarsalia, V., Larsson, M., Nathanson, D., Klein, T., Nyström, T., & Patrone, C. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.17 · Cited by 44
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
Mima, A. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1379274 · Cited by 48
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
“trial.[114] Furthermore, there was an increase in hospitalization for heart failure with saxagliptin in the SAVOR trial, but detailed analysis of the EXAMINE trial found”
BackgroundManrique, C. M., Habibi, J., Aroor, A. R., Sowers, J. R., Jia, G., Hayden, M. R., Garro, M., Martinez‐Lemus, L. A., Ramirez‐Perez, F. I., Klein, T., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0414-5 · Cited by 47
Giugliano, D., Bellastella, G., Longo, M., Scappaticcio, L., Maiorino, M. I., Chiodini, P., & Esposito, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14047 · Cited by 43
Cairano, E. S. D., Moretti, S., Marciani, P., Sacchi, V. F., Castagna, M., Davalli, A. M., Folli, F. B., & Perego, C. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25176 · Cited by 52
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
Diabetes and coronary artery disease: not just a risk factor
Grant, P. J., Cosentino, F., & Marx, N. (2020) · Heart · doi:10.1136/heartjnl-2019-316243 · Cited by 48
Mima, A., Gotoda, H., Lee, R., Murakami, A., Akai, R., & Lee, S. (2023) · Metabolism Open · doi:10.1016/j.metop.2023.100236 · Cited by 48
Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study
Baltzis, D., Dushay, J. R., Loader, J., Wu, J. S., Greenman, R. L., Roustit, M., & Veves, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2655 · Cited by 46
Use of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study
Knapen, L. M., de Jong, R. G. P. J., Driessen, J. H. M., Keulemans, Y. C. A., van Erp, N. P., Bruin, M. L. D., Leufkens, H. G. M., Croes, S., & de Vries, F. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12833 · Cited by 46
“1 years) and EXAMINE (n = 5380, median follow-up 18 months) cardiovascular outcome trials the cases of acute and chronic pancreatitis were similar in the saxagliptin and alogliptin arms as compared with the comparator agent arm.(36,37) The results of observational studies regarding the risk of pancreatitis remain KNAP…”
ResultDarsalia, V., Klein, T., Nyström, T., & Patrone, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.08.022 · Cited by 43
Metadata
- Authors
- White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., Cushman, W. C., & Zannad, F.
- Affiliations
- University of Connecticut (US)
- Brigham and Women's Hospital (US)
- University of Sheffield (GB)
- Cleveland Clinic (US)
- Park Nicollet Health Services (US)
- University of Chicago (US)
- Takeda (United States) (US)
- Harvard University (US)
- Memphis VA Medical Center (US)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1327-1335
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127854619
- Cited by
- 2,502
- References
- 23
- Citations by year
- 2026: 43 · 2025: 60 · 2024: 79 · 2023: 107 · 2022: 124 · 2021: 161 · 2020: 225 · 2019: 243 · 2018: 288 · 2017: 279 · 2016: 329 · 2015: 260 · 2014: 248 · 2013: 44
- FWCI
- 231.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0611-10248)
- National Institutes of Health (UL1TR000041)
- Japan Society for the Promotion of Science (24591075)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- alogliptin, DPP-4 inhibitors, type 2 diabetes, acute coronary syndrome, major adverse cardiovascular events, cardiovascular safety, non-inferiority, HbA1c, acute myocardial infarction, unstable angina, hypoglycemia
- MeSH terms
- Aged, Angina, Unstable, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Piperidines, Uracil, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.